Home › Coronary Artery Disease › Texas › Amarillo
Coronary Artery Disease clinical trials in Amarillo, TX
3 studies for Coronary Artery Disease are looking for participants at sites in and around Amarillo (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
RecruitingPhase 2
- PharmaTex Research, LLC, Amarillo
Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention
RecruitingPhase 4
- PharmaTex Research, Amarillo
- Amarillo Heart Clinical Research Institute, Inc., Amarillo
Dose-finding Study of YMI024 to Assess Efficacy, Safety, and Tolerability in Adults With Stable Coronary Artery Disease and Elevated hsCRP
RecruitingPhase 2
- Pharma Tex Research, Amarillo
About Coronary Artery Disease
Coronary artery disease (CAD) is the most common type of heart disease. It can lead to angina and heart attack. Read about symptoms and tests.
More about Coronary Artery Disease on MedlinePlus
Coronary Artery Disease trials in other cities
- New York City, NY20 studies
- Dallas, TX16 studies
- Boston, MA16 studies
- Atlanta, GA16 studies
- Minneapolis, MN15 studies
- Jacksonville, FL12 studies
- Cleveland, OH12 studies
- Nashville, TN11 studies
- Durham, NC9 studies
- Columbus, OH9 studies
- Plano, TX9 studies
- Philadelphia, PA9 studies
Other studies in Amarillo
- Non-Small Cell Lung Cancer9 studies
- Heart Failure8 studies
- Obesity7 studies
- Lung Cancer5 studies
- Overweight4 studies
- Cardiovascular Disease4 studies
- Blood Clots4 studies
- Breast Cancer4 studies
- Colorectal Cancer3 studies
- Atrial Fibrillation3 studies
- Digestive Diseases3 studies
- Atherosclerosis3 studies
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.